| Catalog No. | HX126026 |
|---|
| Species reactivity | Human |
|---|
| Applications | Research Grade Biosimilar |
|---|
| Host species | Humanized |
|---|
| Isotype | (scFv-heavy-kappa)-(scFv-heavy-lambda)-scFc |
|---|
| Expression system | Mammalian Cells |
|---|
| Clonality | Monoclonal |
|---|
| Target | Claudin-18, CLDN18, T3E, T-cell surface antigen T3/Leu-4 epsilon chain, CD3e, CD3E, T-cell surface glycoprotein CD3 epsilon chain |
|---|
| Concentration | 2mg/ml |
|---|
| Endotoxin level | Please contact the lab for this information. |
|---|
| Purity | >95% purity as determined by SDS-PAGE. |
|---|
| Purification | Protein A/G, purified from cell culture supernatant. |
|---|
| Accession | P56856-2 & P07766 |
|---|
| Form | Liquid |
|---|
| Storage buffer | 0.01M PBS,pH7.4. |
|---|
| Stability and Storage | Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C for short-term storage (1-2 weeks). Store at -20°C for up to 12 months. For long-term storage, store at -733°C. |
|---|
| Alternate Names | Bispecific,AMG910,AMG-910,AMG910CAS:2413817-97-5 |
|---|
| Background | Gresonitamab (AMG 910) is a half-life extended (HLE) bispecific T-cell engager (BiTE) antibody targets CD3-positive T cells and CLDN18.2-expressing tumor cells. Gresonitamab can be used for the research of adenocarcinoma. |
|---|
| Note | For research use only. Not for use in clinical or therapeutic applications. |
|---|
